Vandamme, T., Beyens, M., de Beeck, K. O., Dogan, F., van Koetsveld, P. M., Pauwels, P., . . . Hofland, L. J. (2016). Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors. Br J Cancer.
Chicago-stil citatVandamme, Timon, et al. "Long-term Acquired Everolimus Resistance in Pancreatic Neuroendocrine Tumours Can Be Overcome With Novel PI3K-AKT-mTOR Inhibitors." Br J Cancer 2016.
MLA-referensVandamme, Timon, et al. "Long-term Acquired Everolimus Resistance in Pancreatic Neuroendocrine Tumours Can Be Overcome With Novel PI3K-AKT-mTOR Inhibitors." Br J Cancer 2016.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.